

Kejal Kantarci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6224308/publications.pdf>

Version: 2024-02-01

258
papers

20,448
citations

14655

66
h-index

13379

130
g-index

260
all docs

260
docs citations

260
times ranked

19080
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
2	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.8	581
3	Clinical Proton MR Spectroscopy in Central Nervous System Disorders. <i>Radiology</i> , 2014, 270, 658-679.	7.3	524
4	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012, 71, 765-775.	5.3	520
5	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. <i>Alzheimer's and Dementia</i> , 2018, 14, 1171-1183.	0.8	468
6	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	4.2	391
7	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	5.2	388
8	Non-Stationarity in the "Resting Brain" Modular Architecture. <i>PLoS ONE</i> , 2012, 7, e39731.	2.5	382
9	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.1	365
10	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	7.6	322
11	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	7.6	309
12	Mild Cognitive Impairment and Alzheimer Disease: Regional Diffusivity of Water. <i>Radiology</i> , 2001, 219, 101-107.	7.3	293
13	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	12.8	283
14	Methodological consensus on clinical proton MRS of the brain: Review and recommendations. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 527-550.	3.0	280
15	Clinicopathologic and ¹¹ C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	7.6	270
16	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	2.7	249
17	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
18	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	7.6	218

#	ARTICLE	IF	CITATIONS
19	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 6-15.	1.3	203
20	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. <i>Brain</i> , 2010, 133, 540-556.	7.6	195
21	Neuroimaging in Alzheimer disease: an evidence-based review. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 197-209.	1.0	193
22	Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 2032-2038.	1.1	191
23	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1130.	4.5	185
24	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007, 28, 1330-1339.	3.1	185
25	Association of type 2 diabetes with brain atrophy and cognitive impairment. <i>Neurology</i> , 2014, 82, 1132-1141.	1.1	180
26	Imaging correlates of posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2007, 28, 1051-1061.	3.1	176
27	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	3.1	162
28	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	2.4	162
29	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	3.1	158
30	Brain injury biomarkers are not dependent on β -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	5.3	155
31	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	4.2	155
32	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. <i>NeuroImage</i> , 2008, 42, 559-567.	4.2	152
33	^{145}Tl tau and ^{18}F -amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	5.3	152
34	Effect of lifestyle activities on alzheimer disease biomarkers and cognition. <i>Annals of Neurology</i> , 2012, 72, 730-738.	5.3	149
35	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem ^1H MR Spectroscopy Metabolite Measurements. <i>Radiology</i> , 2008, 248, 210-220.	7.3	147
36	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146

#	ARTICLE	IF	CITATIONS
37	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.1	143
38	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.8	142
39	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 198-207.	1.5	135
40	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 759-764.	5.0	134
41	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
42	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	7.6	126
43	Vascular Imaging Abnormalities and Cognition. <i>Stroke</i> , 2015, 46, 433-440.	2.0	125
44	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	7.7	125
45	Identification of Anonymous MRI Research Participants with Face-Recognition Software. <i>New England Journal of Medicine</i> , 2019, 381, 1684-1686.	27.0	124
46	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	3.6	117
47	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	3.1	113
48	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.8	113
49	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2011, 68, 753-60.	4.5	110
50	¹ H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 934-942.	1.8	109
51	¹⁸ F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	3.1	108
52	Frontotemporal dementia and parkinsonism associated with the IVS1+1G>A mutation in progranulin: a clinicopathologic study. <i>Brain</i> , 2006, 129, 3103-3114.	7.6	105
53	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 856-67.	4.5	99
54	The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084.	2.0	97

#	ARTICLE	IF	CITATIONS
55	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.1	95
56	Early Postmenopausal Transdermal 17 β -Estradiol Therapy and Amyloid- β Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 547-556.	2.6	94
57	Preeclampsia and cognitive impairment later in life. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 74.e1-74.e11.	1.3	93
58	Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. <i>American Journal of Neuroradiology</i> , 2003, 24, 843-9.	2.4	92
59	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.1	91
60	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	4.2	90
61	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. <i>Neurology</i> , 2013, 80, 911-918.	1.1	86
62	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	9.0	81
63	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. <i>NeuroRx</i> , 2004, 1, 196-205.	6.0	80
64	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. <i>Archives of Neurology</i> , 2008, 65, 1621-8.	4.5	75
65	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	7.6	74
66	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.1	73
67	Ante mortem amyloid imaging and β -amyloid pathology in a case with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 878-885.	3.1	69
68	The limbic and neocortical contribution of α -synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2018, 14, 330-339.	0.8	69
69	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	9.0	69
70	Amyloid- β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	7.6	68
71	Entorhinal cortex tau, amyloid- β , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	7.6	68
72	Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions. <i>Diabetes Care</i> , 2011, 34, 184-186.	8.6	66

#	ARTICLE	IF	CITATIONS
73	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With β^2 -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	9.0	65
74	β^2 -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.1	65
75	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. <i>Brain</i> , 2012, 135, 2470-2477.	7.6	64
76	Magnetic resonance spectroscopy, β^2 -amyloid load, and cognition in a population-based sample of cognitively normal older adults. <i>Neurology</i> , 2011, 77, 951-958.	1.1	63
77	Fractional Anisotropy of the Fornix and Hippocampal Atrophy in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 316.	3.4	63
78	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S70-6.	2.2	63
79	Neuroimaging Correlates of Cerebral Microbleeds. <i>Stroke</i> , 2017, 48, 2964-2972.	2.0	63
80	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.2	63
81	Proton MRS in mild cognitive impairment. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 770-777.	3.4	62
82	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.1	62
83	β^2 -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.1	62
84	Magnetic resonance spectroscopy in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 687.	2.2	61
85	In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.1	60
86	Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. <i>Clinical Neurophysiology</i> , 2003, 114, 1724-1728.	1.5	59
87	Focal hemosiderin deposits and β^2 -amyloid load in the ADNI cohort. <i>Alzheimer's and Dementia</i> , 2013, 9, S116-23.	0.8	59
88	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 1681-1689.	1.1	58
89	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.8	58
90	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	9.0	57

#	ARTICLE	IF	CITATIONS
91	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.1	57
92	Cervical spinal cord atrophy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e435.	6.0	57
93	The Role of Diffusion Tensor Imaging in Detecting Microstructural Changes in Prodromal Alzheimer's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 3-9.	3.9	55
94	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	3.9	55
95	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.1	55
96	Midlife and Late-life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	54
97	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.1	53
98	Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. <i>Biology of Sex Differences</i> , 2013, 4, 6.	4.1	52
99	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
100	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	11.6	52
101	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	7.6	51
102	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 493-498.	2.2	49
103	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	5.3	49
104	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. <i>American Journal of Neuroradiology</i> , 2010, 31, 1247-1253.	2.4	48
105	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	9.0	48
106	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.8	48
107	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.1	47
108	Subtypes of dementia with Lewy bodies are associated with α -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.1	47

#	ARTICLE	IF	CITATIONS
109	Myelopathy in Behçet's disease: The Bagel Sign. <i>Annals of Neurology</i> , 2017, 82, 288-298.	5.3	46
110	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.1	45
111	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. <i>Sleep Medicine</i> , 2015, 16, 1502-1510.	1.6	45
112	Magnetic Resonance Spectroscopy in Common Dementias. <i>Neuroimaging Clinics of North America</i> , 2013, 23, 393-406.	1.0	44
113	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. <i>Neurology</i> , 2016, 87, 2317-2323.	1.1	44
114	Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 43-50.	2.4	44
115	Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 339-347.	3.7	43
116	Across-vendor standardization of semi-LASER for single-voxel MRS at 3T. <i>NMR in Biomedicine</i> , 2021, 34, e4218.	2.8	43
117	<i>APOE</i> and cortical superficial siderosis in CAA. <i>Neurology</i> , 2019, 93, e358-e371.	1.1	42
118	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.8	41
119	Lesional REM sleep behavior disorder localizes to the dorsomedial pons. <i>Neurology</i> , 2014, 83, 1871-1873.	1.1	40
120	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	2.0	40
121	Association of common genetic variants with brain microbleeds. <i>Neurology</i> , 2020, 95, e3331-e3343.	1.1	40
122	Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1241-1250.	3.0	38
123	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.8	38
124	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.2	38
125	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021, 12, 7065.	12.8	38
126	White Matter Reference Region in PET Studies of ¹¹ C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- β Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	5.0	37

#	ARTICLE	IF	CITATIONS
127	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	7.6	37
128	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. <i>Brain Communications</i> , 2020, 2, fcaa025.	3.3	37
129	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	12.4	37
130	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	3.1	35
131	Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging. <i>Physiology</i> , 2018, 33, 374-383.	3.1	35
132	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	3.0	34
133	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.8	32
134	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	3.9	32
135	AutoVOI: real-time automatic prescription of volume of interest for single voxel spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1787-1798.	3.0	32
136	Association of white matter microstructural integrity with cognition and dementia. <i>Neurobiology of Aging</i> , 2019, 83, 63-72.	3.1	32
137	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.8	32
138	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. <i>Alzheimer's and Dementia</i> , 2020, 16, 22-36.	0.8	32
139	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	2.7	31
140	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.1	31
141	Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 663-670.	2.8	30
142	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1069-1082.	2.6	30
143	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	2.2	30
144	Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). <i>BMJ Open</i> , 2017, 7, e018861.	1.9	30

#	ARTICLE	IF	CITATIONS
145	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	3.0	30
146	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	3.1	29
147	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	2.0	29
148	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	9.0	29
149	Elevated occipital β -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	1.9	28
150	Reproductive history and progressive multiple sclerosis risk in women. <i>Brain Communications</i> , 2020, 2, fcaa185.	3.3	28
151	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.6	27
152	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	2.2	27
153	Joint associations of β -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	3.1	27
154	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.8	27
155	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.0	27
156	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	2.7	27
157	Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. <i>Physical Therapy</i> , 2014, 94, 289-296.	2.4	26
158	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.8	26
159	¹⁸ F- β -galactosidase uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	3.9	26
160	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	7.6	26
161	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. <i>NeuroImage</i> , 2011, 54, 985-991.	4.2	25
162	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Archives of Neurology</i> , 2011, 68, 1165.	4.5	25

#	ARTICLE	IF	CITATIONS
163	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. <i>Neurology</i> , 2020, 94, e15-e29.	1.1	25
164	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	2.0	24
165	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. <i>Journal of Neurology</i> , 2017, 264, 938-945.	3.6	24
166	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	4.2	24
167	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
168	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.0	23
169	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. <i>Translational Psychiatry</i> , 2021, 11, 483.	4.8	23
170	Revised Self-Monitoring Scale. <i>Neurology</i> , 2020, 94, e2384-e2395.	1.1	23
171	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.1	22
172	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	3.7	22
173	Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	5.9	22
174	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	3.1	21
175	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	3.7	21
176	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	3.1	20
177	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	2.6	19
178	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. <i>Journal of Hypertension</i> , 2017, 35, 2479-2485.	0.5	19
179	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	2.4	19
180	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	19

#	ARTICLE	IF	CITATIONS
181	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	5.9	19
182	Tau- β Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	5.3	19
183	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.8	19
184	¹ H-MRS metabolites and rate of β -amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.1	18
185	Investigation of white matter PiB uptake as a marker of white matter integrity. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 678-688.	3.7	18
186	Confirmation of ¹²³ I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1628-1635.	5.0	18
187	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	3.1	18
188	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. <i>Neurology</i> , 2019, 93, e758-e765.	1.1	18
189	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 5-14.	2.4	17
190	Regional T ₁ relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 774-778.	3.0	17
191	Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis. <i>Menopause</i> , 2018, 25, 625-634.	2.0	17
192	¹⁸ F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	3.3	17
193	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.3	17
194	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	3.7	17
195	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	1.9	16
196	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
197	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	9.0	15
198	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R912-R920.	1.8	15

#	ARTICLE	IF	CITATIONS
199	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.3	15
200	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.8	14
201	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	3.1	14
202	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	3.1	14
203	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	2.6	14
204	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
205	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. <i>Frontiers in Neurology</i> , 2020, 11, 80.	2.4	13
206	β -Amyloid PET and ^{123}I -FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.1	13
207	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	2.0	13
208	Risk factors of neurovascular ageing in women. <i>Journal of Neuroendocrinology</i> , 2020, 32, e12777.	2.6	12
209	Clinicopathological and ^{123}I -FP-CIT SPECT correlations in patients with dementia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 376-381.	3.7	11
210	The value of multimodal imaging with ^{123}I -FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	3.1	11
211	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	12.8	11
212	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	3.9	11
213	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. <i>Maturitas</i> , 2018, 117, 64-77.	2.4	10
214	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	10
215	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. <i>Neurocase</i> , 2012, 18, 1-12.	0.6	9
216	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenocopy in Mapt Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	2.0	9

#	ARTICLE	IF	CITATIONS
217	Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study. <i>Menopause</i> , 2020, 27, 305-310.	2.0	9
218	Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations. <i>NMR in Biomedicine</i> , 2021, 34, e4325.	2.8	9
219	Decreased glutamine and glutamate: an early biomarker of neurodegeneration. <i>International Psychogeriatrics</i> , 2021, 33, 1-2.	1.0	9
220	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	2.0	9
221	¹ H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	3.1	9
222	Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy. <i>Menopause</i> , 2020, 27, 872-878.	2.0	8
223	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.6	8
224	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12299.	2.4	8
225	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	2.2	7
226	Development of ¹ H MRS biomarkers for tracking early predementia Alzheimer disease. <i>Neurology</i> , 2019, 92, 209-210.	1.1	7
227	Long-term ovarian hormone deprivation alters functional connectivity, brain neurochemical profile and white matter integrity in the Tg2576 amyloid mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 102, 139-150.	3.1	7
228	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. <i>Neurology</i> , 2014, 83, 1771-1772.	1.1	6
229	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2016, 139, 1005-1007.	7.6	6
230	Face recognition from research brain PET: An unexpected PET problem. <i>NeuroImage</i> , 2022, 258, 119357.	4.2	6
231	Frequency of Acute and Subacute Infarcts in a Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 300-306.	3.0	5
232	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. <i>Frontiers in Neurology</i> , 2021, 12, 615024.	2.4	5
233	Sleep quality and cortical amyloid- β deposition in postmenopausal women of the Kronos early estrogen prevention study. <i>NeuroReport</i> , 2021, 32, 326-331.	1.2	5
234	Plug-and-play advanced magnetic resonance spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 2613-2620.	3.0	5

#	ARTICLE	IF	CITATIONS
235	Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy. <i>Annals of Neurology</i> , 2022, 92, 358-363.	5.3	5
236	Diffusion Tensor Imaging in Alzheimers Disease. <i>Current Medical Imaging</i> , 2011, 7, 28-33.	0.8	4
237	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	3.6	4
238	Peripheral Markers of Neurovascular Unit Integrity and Amyloid- β^2 in the Brains of Menopausal Women. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 397-405.	2.6	4
239	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	2.6	4
240	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 264-268.	2.0	3
241	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
242	MR spectroscopy, <i>APOE</i> genotype, and evolving β^2 -amyloid pathology. <i>Neurology</i> , 2016, 86, 1750-1751.	1.1	2
243	[O β]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPALUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL. <i>Alzheimer's and Dementia</i> , 2017, 13, P570.	0.8	2
244	Reply to letter: Basis of cingulate island sign may differ in dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 761-762.	3.9	2
245	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Journal of Neuroimaging</i> , 2013, 23, 409-413.	2.0	1
246	Multimodal imaging in RBD – present and future. <i>Nature Reviews Neurology</i> , 2018, 14, 574-576.	10.1	1
247	Proton MR spectroscopy in aging and dementia. , 0, , 618-629.		0
248	Imaging markers offer promise. <i>Neurology</i> , 2012, 79, 2296-2297.	1.1	0
249	Early indications of magnetic resonance spectroscopy changes associated with β^2 -amyloid load in the cognitively normal. <i>Future Neurology</i> , 2012, 7, 117-118.	0.5	0
250	Dementia and Alzheimer Disease: Evidence-Based Neuroimaging. , 2013, , 283-298.		0
251	Past hormone therapy in older women. <i>Neurology</i> , 2014, 82, 380-381.	1.1	0
252	Magnetic Resonance Spectroscopy in Dementia. , 2016, , 55-70.		0

#	ARTICLE	IF	CITATIONS
253	[O1â€™02â€™04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.8	0
254	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. <i>Journal of Human Hypertension</i> , 2018, 32, 385-385.	2.2	0
255	Reply to â€œAmyloid Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damageâ€: <i>Annals of Neurology</i> , 2020, 87, 988-989.	5.3	0
256	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1907-1909.	3.4	0
257	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
258	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	0